Effect of suppressive oligodeoxynucleotides on the development of inflammation-induced papillomas

Cancer Prevention Research

Volumn 4, Issue 5, 2011, Pages 752-757

  Ikeuchi, Hidekazu ^a   Kinjo, Takeshi ^a   Klinman, Dennis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCL2; CHEMOKINE RECEPTOR CXL2; CYCLOOXYGENASE 2; OLIGODEOXYNUCLEOTIDE; ORNITHINE DECARBOXYLASE; PHORBOL 13 ACETATE 12 MYRISTATE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOINFLAMMATORY DISEASE; CANCER INHIBITION; CARCINOGENESIS; CELL INFILTRATION; DISEASE MARKER; DOSE RESPONSE; FEMALE; GENETIC CODE; HYPERPLASIA; LEUKOCYTE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SHOCK; SKIN EDEMA; SKIN PAPILLOMA; UPREGULATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CHEMOKINE CCL2; CHEMOKINE CXCL2; CYCLOOXYGENASE 2; FEMALE; INFLAMMATION; MICE; OLIGODEOXYRIBONUCLEOTIDES; ORNITHINE DECARBOXYLASE; PAPILLOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE;

EID: 79955858837     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0290     Document Type: Article

References (38)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. (Pubitemid 36019639)
3. Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol 2003;171:1393-400. (Pubitemid 36900072)
4. Dong L Ito S, Ishii K, Klinman D. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong the survival of lupus-prone NZB/W mice. Arthritis Rheum 2004;52:651-8. (Pubitemid 40216332)
5. Zeuner RA, Ishii KJ, Lizak MJ, Gursel I, Yamada H, Klinman DM, et al. Reduction of GpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum 2002;46:2219-24.
6. Zeuner RA, Verthelyi D, Gursel M, Ishii KJ, Klinman DM. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum 2003;48:1701-7. (Pubitemid 36682379)
7. Shirota H, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma- and IL-12-mediated signaling. J Immunol 2004;173:5002-7. (Pubitemid 39402951)
8. Shirota H, Gursel I, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol 2005;174:4579-83.
9. Abel EL, Angel JM, Kiguchi K, DiGiovanni J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc 2009;4:1350-62.
10. Auvinen M. Cell transformation invasion and angiogenesis: a regulatory role for ornithine decarboxylase and polyamines? J Natl Cancer Inst 1997;89:533-7.
11. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470:M69-78.
12. Katiyar SK, Rupp CO, Korman NJ, Agarwal R, Mukhtar H. Inhibition of 12-O-tetradecanoylphorbol-13-acetate and other skin tumor-promoter-caused induction of epidermal interleukin-1 alpha mRNA and protein expression in SENCAR mice by green tea polyphenols. J Invest Dermatol 1995;105:394-8.
13. Sato T, Shimosato T, Alvord WG, Klinman DM. Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation. J Immunol 2008;180:7648-54.
14. Scholz K, Furstenberger G, Muller-Decker K, Marks F. Differential expression of prostaglandin-H synthase isoenzymes in normal and activated keratinocytes in vivo and in vitro. Biochem J 1995;309:263-9.
15. O'Brien TG, Simsiman RC, Boutwell RK. Induction of the polyamine-biosynthetic enzymes in mouse epidermis by tumor-promoting agents. Cancer Res 1975;35:1662-70.
16. Wang HQ, Smart RC. Overexpression of protein kinase C-alpha in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2 MIP-2 and TNF-alpha expression but not tumor promotion. J Cell Sci 1999;112:3497-506.
17. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
18. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9. (Pubitemid 47517504)
19. Klinman DM, Xie H, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann N Y Acad Sci 2006;1082:137-50. (Pubitemid 44955459)
20. Lewis JG, Adams DO. Early inflammatory changes in the skin of SENCAR and C57BL/6 mice following exposure to 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis 1987;8:889-98. (Pubitemid 17133576)
21. Cataisson C, Ohman R, Patel G, Pearson A, Tsien M, Jay S, et al. Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis. Cancer Res 2009;69:319-28.
22. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999;5:828-31. (Pubitemid 29318619)
23. Dunn GP, Koebel CM, Schreiber RD. Interferons immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
24. Afaq F, Saleem M, Krueger CG, Reed JD, Mukhtar H. Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice. Int J Cancer 2005;113:423-33. (Pubitemid 40038710)
25. Thomas T, Thomas TJ. Polyamine metabolism and cancer. J Cell Mol Med 2003;7:113-26. (Pubitemid 37123597)
26. Mohan RR, Challa A, Gupta S, Bostwick DG, Ahmad N, Agarwal R, et al. Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 1999;5:143-7. (Pubitemid 29045187)
27. Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 1994;13:241-56.
28. Hirschowitz E, Hidalgo G, Doherty D. Induction of cyclo-oxygenase-2 in non-small cell lung cancer cells by infection with DeltaE1 DeltaE3 recombinant adenovirus vectors. Gene Ther 2002;9:81-4. (Pubitemid 34145171)
29. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000;51:511-23. (Pubitemid 30216052)
30. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:88-93. (Pubitemid 32006467)
31. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib a specific cyclooxygenase-2 inhibitor against colon carcinogenesis. Cancer Res 1998;58:409-12. (Pubitemid 28087398)
32. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000;60:5599-602.
33. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998;58:5354-60. (Pubitemid 28551116)
34. Muller-Decker K, Kopp-Schneider A, Marks F, Seibert K, Furstenberger G. Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. Mol Carcinog 1998;23:36-44. (Pubitemid 28441058)
35. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, et al. Chemopreventive activity of celecoxib a specific cyclooxygenase-2 inhibitor and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999;25:231-40. (Pubitemid 29372908)
36. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999;20:1939-44. (Pubitemid 29476120)
37. Furstenberger G, Gross M, Marks F. Eicosanoids and multistage carcinogenesis in NMRI mouse skin: role of prostaglandins E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion). Carcinogenesis 1989;10:91-6. (Pubitemid 19032090)
38. Klinman DM, Gursel I, Klaschik S, Dong L, Currie D, Shirota H. Therapeutic potential of oligonucleotides expressing immunosuppressive TTAGGG motifs. Ann N Y Acad Sci 2005;1058:87-95.